A pilot study of Cognitive Behavioral Therapy for Generalized Anxiety Disorder.

False Safety Behavior Elimination Therapy for Generalized Anxiety Disorder-Randomized Clinical Trial Comparing Cognitive Behavioral Therapy and Pharmacological Treatment. - A pilot study of Cognitive Behavioral Therapy for Generalized Anxiety Disorder.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs031190044

Enrollment

Registered

2019-06-25

Start date

2019-09-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Generalized Anxiety Disorder

Interventions

Cognitive Behavioral Therapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1)Primary diagnosis of Generalized Anxiety Disorder using the Mini- International Neuropsychiatric Interview, DSM-5. (2)The age between 18 to 65. (3)Patients with full consent of participation in the study. (4)Patients' PSWQ score is above 45. (5)No change of medical drugs during the study. (6)Possible to understand cognitive behavioral therapy, and has mental and physical condition that can be participate the session for at least one year. (7)If Generalized Anxiety Disorder is primary diagnosed, patients with Social Anxiety Disorder, Major Depressive Disorder, Agoraphobia will not be excluded from the study.

Exclusion criteria

Exclusion criteria: 1. Psychosis, major depression, bipolar, organic brain disorder, substance abuse or dependence, other severe mental, physical condition. 2. Active suicidality 3. Repetitive anti-social behavior 4. Severe physical condition 5. IQ under 80;JART25: Japanese Adult Reading Test25 6. Autistic Spectrum Disorder 7. Patients who cannot contact with the study organizer 8. Other relevant reason decided by the investigators

Design outcomes

Primary

Measure	Time frame
Mean Change From Baseline in Penn State Worry Questionnaire (PSWQ) Score [ Time Frame: Baseline , 5 weeks ]	—

Secondary

Measure	Time frame
Mean change from baseline to 5 weeks and 9 weeks of the following scales (9 weeks is only for COMB group). 1. Penn State Worry Questionnaire Score 2. Patient Health Questionnaire-9 3. Generalized Anxiety Disorder -7 4. EuroQOL5dimension 5. Subtle Avoidance Frequency Examination 6. Anxiety Control Questionnaire 7. Beck Depression Inventory II 8. Sheehan Disability Scale 9. Clinical Global Impression -Severity 10. Beck Anxiety Inventory 11. Name of psychotropic drug and daily dose	—

Measure

Time frame

Mean change from baseline to 5 weeks and 9 weeks of the following scales (9 weeks is only for COMB group). 1. Penn State Worry Questionnaire Score 2. Patient Health Questionnaire-9 3. Generalized Anxiety Disorder -7 4. EuroQOL5dimension 5. Subtle Avoidance Frequency Examination 6. Anxiety Control Questionnaire 7. Beck Depression Inventory II 8. Sheehan Disability Scale 9. Clinical Global Impression -Severity 10. Beck Anxiety Inventory 11. Name of psychotropic drug and daily dose

—

Contacts

Public ContactHonami Arai

Chiba University

aypa1127@chiba-u.jp+81-43-226-2975

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026